Onxeo SA (EUR)
ONXEO
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range0.53 | 0.55
52-Wk Range0.50 | 1.05
Last Close0.54
Mkt Cap (m)29.71
Dividend yield-
ISINFR0010095596
Volume83,012
Exchange VenuePAR

Company Profile

Onxeo SA is engaged in the development of drugs for the treatment of orphan diseases in particular in oncology. Its pipeline products include AsiDNA 1V, AsiDNA+chemo/radio, AsiDNA+Belinostat/HDACi and others.

Key Information
Price/Earning-
Price/Book0.76
Price/Sales5.22
P/CF-
Rev Growth (3 year avg)20.73
EPS Growth (3 year avg)-
Operating Margin % -255.31
Net Margin %-153.40
Return on Equity-19.73
Debt/Equity0.01

Legal Documents

Annual Report
en 31/12/2018

Financials

Income Statement
EUR201320142015201620172018
Revenue (m)12234106
Operating Income (m)-15-1-22-23-66-16
Net Income (m)-15-8-19-23-59-9
Basic EPS-0.74-0.19-0.48-0.48-1.17-0.18
Avg. Diluted Shares Outstanding (m)214141475153
Balance Sheet
EUR201320142015201620172018
Current Assets (m)166342373120
Non Current Assets (m)18988884843
Total Assets (m)181521291257863
Current Liabilities (m)7131112198
Total Liabilities (m)------
Total Equity (m)7122103945045
Cash Flows
EUR201320142015201620172018
Operating Cash Flows (m)-14-8-23-18-28-11
Capital Expenditure (m)-1
Figures are quoted in EUR unless stated otherwise
-0.01 (-1.87%)
0.53
Last Price